MIRAPEX ER
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRAPEX ER is an extended-release oral tablet containing pramipexole, a dopamine agonist approved in 2010. The drug's mechanism of action and specific indications are not disclosed in available data, but dopamine agonists are commonly used for movement disorders and restless leg syndrome. Patient eligibility and dosing depend on the primary indication.
$0.794MPart D
LOE ApproachingAs LOE approaches, the brand team is likely in defensive/transition mode with reduced headcount and investment shifting to generic conversion management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MIRAPEX ER in 2024 presents a challenging career scenario: zero linked job openings and an approaching LOE signal limited growth potential and team expansion. This role is best suited for professionals seeking stability in transition management or those looking to develop expertise in late-lifecycle product strategy.
Brand ManagerMedical Science Liaison
Worked on MIRAPEX ER at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.